Achieving Control: Optimizing the Management of CKD-Anemia
CME 2008 (Satellite Symposium)
March 16, 2008 - Austin, Texas
HDCN free zone registration is required. If you don't already have one,
click here to register and get an HDCN username and password.
Welcome and Introductory Remarks
Allen R. Nissenson, MD
Emerging Issues in Anemia Management of CKD: Putting it into Perspective
Steven Fishbane, MD

Rationale to Optimize Patient Response and Clinical Outcomes
Michael J. Germain, MD

Multidisciplinary Practice Models: Reengineering Clinical Operations to Improve CKD Outcomes
Robert Provenzano, MD

Questions and Answers

Allen R. Nissenson, MD
Professor of Medicine, Associate Dean, and Director, Dialysis Program. David Geffen School of Medicine at UCLA, Losa Angeles, California.

Steven Fishbane, MD
Chief, Division of Nephrology and Hypertension, Department of Medicine, Professor of Medicine, SUNY at Stony Brook School of Medicine, Stony Brook, New York

Michael J. Germain, MD
Assistant Professor of Medicine, Tufts University School of Medicine, Boston, Massachusetts

Robert Provenzano, MD
Medical Director, Transplant Program Section Chief, Nephrology, St. John Hospital & Medical Center, Detroit, Michigan

Physicians click on the blue button to obtain CME credit.

Other health care professionals, please click on the gray button to obtain a certificate of completion.
This educational activity is an audio recording with accompanying slides of a live presentation held March 16, 2008, in Austin, Texas. Continuing medical education credit will be awarded to physicians who successfully complete this activity with a score of 75% or better on the post-test and return an evaluation. Participation should take approximately 1.5 hours.

To complete this activity and receive credit, the participant should listen to the talks, scroll down to review the accompanying slides, review the PubMed abstracts of the linked slides and references, complete the post-test and evaluation, and read the abstracts linked to the post-test feedback section.

Release Date: May 15, 2008
Review/Approval Date: May 15, 2008
Expiration Date: May 15, 2009
AMA PRA Category 1 Credits™: 1.5

To complete this educational activity, the user will need Windows (XP or higher) or Macintosh (version 9.0 or higher) operating software, a connection to the internet with a 28.8 kbps MODEM or better. The computer should have an audio card with speakers. An audio player, either the Windows Media Player (downloadable from the Real Player from Real Media ( is required and either can be downloaded for free per instructions on the individual lecture pages. Flash 8.0 (from is required to see the full-screen slide/audio presentations and the video presentations. Acrobat Reader is required to print the CME certificate, and this can be download free from

For questions regarding CME credit, the post-test, or evaluation, please call Penn State continuing Education at (717) 531-6483 or e-mail Please reference activity code G3852-08-T
This educational activity was supported by an educational grant from Ortho Biotech.

Program Overview
Anemia is a complication of chronic kidney disease (CKD) that is seen in more than 80% of patients with impaired renal function. Although there are many mechanisms involved in the pathogenesis of renal anemia, the primary cause is the inadequate production of erythropoietin by the damaged kidneys. Recent reports from the third National Health and Nutrition Examination Survey indicate that approximately 20 million people in the United States may have chronic kidney disease (CKD), and patients with CKD, independent of diabetic status, have a 5-10-fold higher risk of death than those reaching end-stage renal disease. Evidence indicates that anemia develops early in the disease and becomes more severe as renal function declines. Anemia is associated with multiple adverse outcomes such as fatigue, decreased health-related quality of life, decreased mental capacity and cardiovascular-related complications and, as such, represents an important public health issue.

Learning Objectives
At the conclusion of this program, participants will be able to:
  • Describe the clinical and pharmacoeconomic consequences and importance of treating anemia of chronic kidney disease
  • Review the safety and efficacy of erythropoiesis-stimulating agents from recent randomized trials
  • Distinguish between erythropoiesis-stimulating agents and its potential impact on patient response
  • Discuss the multidisciplinary approach to practice management to realize improved clinical outcomes and cost efficiencies as a model of quality improvement
Target Audience
This CME symposium is intended for renal physicians.

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Penn State College of Medicine and SynerMed® Communications. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians

Credit Designation
Penn State College of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Penn State College of Medicine is committed to offering CME programs which promote improvements or quality in health care and are developed free of the control of commercial interests. Reasonable efforts have been taken to ensure that our programs are balanced, independent, objective, scientific, and in compliance with regulatory requirements. Faculty and course directors have disclosed all relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest. Penn State also requires that faculty disclose any discussion of off-label or investigational uses included in their presentations. Disclosure of a relationship is not intended to suggest or condone bias in a presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Allen R. Nissenson, MD has served on the Speakers bureau for Watson Pharmaceuticals, Inc. He has served as a consultant for Advanced Magnetics Inc., Affymax, Inc., DaVita Inc., FibroGen, Inc., and Hoffman-La Roche Inc. He has received research grants from Amgen Inc., Hoffman-La Roche Inc., and the NIH.

Steven Fishbane, MD has served on the Speakers bureau for Ortho and Amgen inc. He has served as a consultant and received research grants from Amgen Inc., Hoffman-La Roche Inc., and Affymax, Inc.

Michael J. Germain, MD has served on the Speakers bureau for Amgen Inc. and Novartis Pharmaceuticals. He has served as a consultant for Amgen Inc., Hoffman-La Roche Inc., Ortho, and Novartis Pharmaceuticals Corp. He owns stock in Amgen Inc. He received research grants from Amgen Inc. and Novartis Pharmaceuticals Corp.

Robert Provenzano, MD has served on the Speakers bureau for Ortho Biotech, Inc., Amgen Inc., Affymax, Inc., and Hoffman-La Roche Inc. He has served as a consultant for DaVita Inc., Advanced Magnetics Inc., and Ortho Biotech. Inc. He has received research grants from Advanced Magnetics Inc., Ortho Biotech, Inc., Amgen Inc. /Affymax, Inc., and Hoffman-La Roche Inc. He has employment affiliation with DaVita Inc.

Penn State and SynerMed staff involved in the development of this activity have no financial relationships relevant to the content of this activity.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of. or promotion by, Penn State College of Medicine. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

The content and views presented in this educational program are those of the faculty and do not necessarily reflect those of SynerMed and Penn State College of Medicine. Before prescribing any medicine, primary references and full prescribing information should be consulted.

Off-label/lnvestigational Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Before prescribing any medication, physicians should consult primary references and full prescribing information. The faculty presenters will disclose if any unlabeled use of products is mentioned in their presentations. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Penn State Privacy Policy
Penn State is committed to on-line privacy and confidentiality. This website is managed by HDCN, and their printed privacy policy applies to this site. CME credit for "Achieving Control: Optimizing the Management of CKD-Anemia" is provided by Penn State College of Medicine. If you register for CME credit for this educational activity, HDCN will forward relevant personally identifiable information to Penn State College of Medicine so that we can maintain records concerning credits we issue to you. We may share aggregated data concerning registrations, post-tests, and evaluations on request of our joint sponsor (SynerMed Communications) and/or the commercial supporter. We will not share any personally identifiable information. Penn State College of Medicine may use the information you provide on this site to contact you about your CME credit or other relevant educational activities provided through Penn State College of Medicine. For more information, contact

The CME policy statements of HDCN are listed on this page.